HER2 assessment in locally advanced gastric cancer: comparing the results obtained with the use of two primary tumour blocks versus those obtained with the use of all primary tumour blocks

Histopathology
Chen XuJing Qin

Abstract

HER2 is currently the only biomarker used to select eligible patients with advanced gastric cancer (GC) for targeted therapy. The aims of this study were to verify the value of dual-block HER2 assessment and to explore whether increasing the block number is more beneficial by carrying out a randomized prospective cohort study in which dual-block and all-block HER2 assessment were compared in resected specimens of GC. Five hundred and forty-nine resected GC specimens were randomly enrolled into two cohorts: a dual-block group (n = 274) with two primary tumour blocks tested, and an all-block group (n = 275) with all primary tumour blocks tested. Immunohistochemical staining of HER2 was performed. For HER2-equivocal (2+) cases, fluorescence in-situ hybridization (FISH) was performed. As compared with single-block assessment, dual-block assessment increased the HER2 immunohistochemistry (IHC)-positive (3+) rate. The rate with dual-block assessment (11.3%) was significantly higher than that with block 1 assessment (8.8%) (P = 0.016) and block 2 assessment (9.1%) (P = 0.031). Similarly, all-block assessment demonstrated a higher HER2 3+ rate (12.4%) than single-block assessment (block 1, 6.5%; block 2, 6.2%; block 3, 7.2%; block 4, 8...Continue Reading

References

Jan 26, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M TannerJ Isola
Aug 5, 2008·Gastrointestinal Endoscopy Clinics of North America·Kentaro Sugano
Feb 27, 2010·Oncology·Jan Trøst Jørgensen
Jul 29, 2010·Virchows Archiv : an International Journal of Pathology·Josef RüschoffH H Kreipe
Aug 27, 2010·Clinical Otolaryngology : Official Journal of ENT-UK ; Official Journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery·V PaleriR G Wight
Jan 10, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Josef RüschoffGiuseppe Viale
Jan 13, 2012·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Mar 6, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Hyesil SeolSo Yeon Park
Nov 10, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V S WarnekeC Röcken
Dec 15, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Eun Yoon ChoSung Kim
Apr 2, 2013·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Vincenzo ArenaArnaldo Carbone
Sep 16, 2014·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayFreddie Bray
Sep 18, 2014·Asia-Pacific Journal of Clinical Oncology·Kyoung-Mee KimSheng Zhang
Oct 31, 2014·Archives of Pathology & Laboratory Medicine·Brandon S SheffieldDavid F Schaeffer
Dec 17, 2014·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Shih-Chiang HuangTse-Ching Chen
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Jan 16, 2016·Current Oncology Reports·Sophia C KamranJennifer Y Wo
Jan 26, 2016·CA: a Cancer Journal for Clinicians·Wanqing ChenJie He

❮ Previous
Next ❯

Citations

Aug 11, 2018·Expert Review of Anticancer Therapy·Imane El Dika, David H Ilson
Jun 7, 2019·Current Opinion in Oncology·Anna D WagnerJosef Rüschoff
Mar 3, 2020·Pathology, Research and Practice·Yanfeng XiYingyong Hou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.